Fortress Biotech (FBIO) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fortress Biotech (FBIO) has outperformed NeOnc Technologies (NTHI) over the past year, losing 28.2% versus a loss of 79.1%. NeOnc Technologies is the larger company by market cap ($80.1 million vs $71.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | NTHI |
|---|---|---|
| Share price | $2.14 | $2.78 |
| Market cap | $71.20M | $80.08M |
| 1-day change | +2.15% | +9.88% |
| YTD return | -42.90% | -69.41% |
| 1-year return | -28.18% | -79.07% |
| 5-year return | -95.48% | — |
| P/E ratio (TTM) | 0.77 | — |
| EPS (TTM) | $2.76 | $-2.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.53 | $12.09 |
| 52-week low | $2.00 | $2.50 |
| Distance from 52-week high | -52.87% | -77.01% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +134.19% | +511.51% |
| Average volume | 495.05K | 195.17K |
| Shares outstanding | 33.35M | 28.81M |
| Employees | 78 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FBIO has outperformed NTHI by 50.9 percentage points over the past year.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
FBIO vs NTHI FAQ
Which is bigger, Fortress Biotech or NeOnc Technologies?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $80.08M compared with $71.20M for Fortress Biotech (FBIO).
Which stock has performed better over the past year, FBIO or NTHI?
FBIO returned -28.18% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.